Published in J Bone Miner Res on June 01, 2006
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33
Health disparities in endocrine disorders: biological, clinical, and nonclinical factors--an Endocrine Society scientific statement. J Clin Endocrinol Metab (2012) 2.78
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract (2011) 2.29
Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol (2007) 1.88
Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause (2008) 1.74
Effect of hormone therapy on lean body mass, falls, and fractures: 6-year results from the Women's Health Initiative hormone trials. Menopause (2011) 1.56
Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause (2011) 1.55
Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial. Menopause (2013) 1.42
Individualizing osteoporosis therapy. Osteoporos Int (2012) 1.15
Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol (2013) 1.10
Postmenopausal estrogen and progestin effects on the serum proteome. Genome Med (2009) 1.07
Low-fat, increased fruit, vegetable, and grain dietary pattern, fractures, and bone mineral density: the Women's Health Initiative Dietary Modification Trial. Am J Clin Nutr (2009) 0.98
Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab (2009) 0.91
Women's Health Initiative clinical trials: interaction of calcium and vitamin D with hormone therapy. Menopause (2014) 0.89
What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? Osteoporos Int (2010) 0.89
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract (2011) 0.88
Influence of hysterectomy on long-term fracture risk. Fertil Steril (2007) 0.86
Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke. Semin Reprod Med (2014) 0.82
Baseline serum estradiol and fracture reduction during treatment with hormone therapy: the Women's Health Initiative randomized trial. Osteoporos Int (2009) 0.81
The ovariectomized rat as a model for studying alveolar bone loss in postmenopausal women. Biomed Res Int (2015) 0.80
Menopause, Reproductive Life, Hormone Replacement Therapy, and Bone Phenotype at Age 60-64 Years: A British Birth Cohort. J Clin Endocrinol Metab (2016) 0.78
Proteomic profiling of the autoimmune response to breast cancer antigens uncovers a suppressive effect of hormone therapy. Proteomics Clin Appl (2013) 0.76
Progress in mining the human proteome for disease applications. OMICS (2011) 0.76
Medical treatment of osteoporotic vertebral fractures. Ther Adv Musculoskelet Dis (2011) 0.76
The tissue selective estrogen complex: a promising new menopausal therapy. Pharmaceuticals (Basel) (2012) 0.76
Menopausal Hormone Therapy, Age, and Chronic Diseases: Perspectives on Statistical Trends. Chem Res Toxicol (2016) 0.75
Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan. Osteoporos Int (2014) 0.75
Estrogen treatment does not reduce fractures? Menopause (2014) 0.75
Long-term supplementation with young coconut juice does not prevent bone loss but rather alleviates body weight gain in ovariectomized rats. Biomed Rep (2017) 0.75
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med (2013) 15.58
Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50
Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med (2002) 7.77
The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol (2003) 7.49
Association of weight status with mortality in adults with incident diabetes. JAMA (2012) 7.49
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med (2009) 7.06
Association of long-distance corridor walk performance with mortality, cardiovascular disease, mobility limitation, and disability. JAMA (2006) 6.93
Frailty: emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study. J Am Geriatr Soc (2005) 6.73
Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66
Calcium/vitamin D supplementation and cardiovascular events. Circulation (2007) 6.63
Prognostic value of usual gait speed in well-functioning older people--results from the Health, Aging and Body Composition Study. J Am Geriatr Soc (2005) 6.54
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med (2012) 6.46
Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med (2006) 6.22
Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA (2008) 6.00
Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med (2004) 5.65
Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med (2010) 5.60
Racial differences in incident heart failure among young adults. N Engl J Med (2009) 5.60
Smoking and mortality--beyond established causes. N Engl J Med (2015) 5.54
Effects of estrogen with and without progestin on urinary incontinence. JAMA (2005) 5.41
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22
Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA (2011) 5.21
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
High-trauma fractures and low bone mineral density in older women and men. JAMA (2007) 5.00
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
Effects of estrogen plus progestin on health-related quality of life. N Engl J Med (2003) 4.83
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55
Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA (2003) 4.54
Fast food restaurants and food stores: longitudinal associations with diet in young to middle-aged adults: the CARDIA study. Arch Intern Med (2011) 4.40
Use of recovery biomarkers to calibrate nutrient consumption self-reports in the Women's Health Initiative. Am J Epidemiol (2008) 4.28
Hearing loss and cognitive decline in older adults. JAMA Intern Med (2013) 4.25
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
Association between radiographic features of knee osteoarthritis and pain: results from two cohort studies. BMJ (2009) 3.99
Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med (2006) 3.91
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85
Health plan members' views about disclosure of medical errors. Ann Intern Med (2004) 3.69
Cognitive function, gait speed decline, and comorbidities: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci (2007) 3.61
Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst (2008) 3.60
Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med (2005) 3.56
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol (2012) 3.56
Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med (2010) 3.53
Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol (2006) 3.53
Limited literacy and mortality in the elderly: the health, aging, and body composition study. J Gen Intern Med (2006) 3.51
Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol (2012) 3.47
Estrogen plus progestin and risk of venous thrombosis. JAMA (2004) 3.46
Validity of self-report for fractures among a multiethnic cohort of postmenopausal women: results from the Women's Health Initiative observational study and clinical trials. Menopause (2004) 3.33
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet (2013) 3.31
Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev (2005) 3.20
Meniscal tear in knees without surgery and the development of radiographic osteoarthritis among middle-aged and elderly persons: The Multicenter Osteoarthritis Study. Arthritis Rheum (2009) 3.19
Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. J Am Soc Nephrol (2005) 3.14
Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA (2002) 3.13